Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


J Am Soc Nephrol 15: 2477-2485, 2004
© 2004 American Society of Nephrology
doi: 10.1097/01.ASN.0000138546.53152.A7

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eggers, P. W.
Right arrow Articles by Kimmel, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eggers, P. W.
Right arrow Articles by Kimmel, P. L.
J Am Soc Nephrol 15:2477-2485, 2004
© 2004 American Society of Nephrology


CLINICAL SCIENCE

Is There an Epidemic of HIV Infection in the US ESRD Program?

Paul W. Eggers and Paul L. Kimmel

Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland; and Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, Washington, DC.

Correspondence to Dr. Paul L. Kimmel, Division of Renal Diseases and Hypertension, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Ave NW, Washington, DC 20037. Phone: 202-741-2283; Fax: 202-741-2285; E-mail: pkimmel{at}mfa.gwu.edu

Surveys revealed increases in the prevalence of HIV-infected patients in the US end-stage renal disease (ESRD) program in the 1980s and early 1990s, with clustering in young black men 25 to 44 yr old. Since the availability of highly active antiretroviral therapy in 1996, the prognosis of HIV-infected patients has improved, and therapy has been shown to change the course of classic HIV-associated nephropathy. We used the United States Renal Data System database to determine if the incidence and prevalence of HIV-infected patients with renal disease has increased in the ESRD program, by means of principal diagnoses and comorbid AIDS-defining diagnoses.

As the number of US patients living with AIDS increased 57% from 214,711 in 1995 to 337,017 in 2000, and the number of incident ESRD patients increased 29.9% from 72,827 to 94,602, the number of incident HIV-infected patients increased only by 3.5%, from 1133 to 1171. Over this time, the percentage of incident ESRD patients with HIV infection fell from 1.56% to 1.24%. Among black men 25 to 44 yr of age, HIV infection as a proportion of incident ESRD cases fell from 8.5% to 6.2% from 1995 to 2000. The incident rate per million of AIDS or HIV infection in black men aged 25 to 44 fell from 107 in 1995 to 78 per million in 2000. The incidence rate for HIV-infected women in the ESRD program rose 14% while it declined 7% in men. Almost 2000 HIV-infected women, or 28.8% of the population, have initiated therapy for ESRD with hemodialysis. The number of prevalent cases increased in absolute numbers 81.3% from 2687 to 4871 (0.90% to 1.16% of the ESRD program). One-year survival rates for HIV-infected incident ESRD patients increased from 53.1% to 67.1% from 1995 to 2000.

Although these values may be underestimates because of underreporting due to confidentiality concerns and lack of biopsy confirmation, we conclude that although the prevalence of HIV infection is increasing in the US ESRD population, the increase as a proportion of the program is minimal and is due to better survival after development of renal failure. The incidence of HIV infection in the US ESRD program is stable. Highly active antiretroviral therapy may be responsible for the change in epidemiology of HIV infection in the US ESRD program.




This article has been cited by other articles:


Home page
Arch Intern MedHome page
M. C. Odden, R. Scherzer, P. Bacchetti, L. A. Szczech, S. Sidney, C. Grunfeld, and M. G. Shlipak
Cystatin C Level as a Marker of Kidney Function in Human Immunodeficiency Virus Infection: The FRAM Study
Arch Intern Med, November 12, 2007; 167(20): 2213 - 2219.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
L. M. McKenzie, S. L. Hendrickson, W. A. Briggs, R. A. Dart, S. M. Korbet, M. H. Mokrzycki, P. L. Kimmel, T. S. Ahuja, J. S. Berns, E. E. Simon, et al.
NPHS2 Variation in Sporadic Focal Segmental Glomerulosclerosis
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2987 - 2995.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. I. Choi, R. A. Rodriguez, P. Bacchetti, D. Bertenthal, P. A. Volberding, and A. M. O'Hare
Racial Differences in End-Stage Renal Disease Rates in HIV Infection versus Diabetes
J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2968 - 2974.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
S. D. Cohen and P. L. Kimmel
HIV-associated renal diseases in Africa a desperate need for additional study
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2116 - 2119.
[Full Text] [PDF]


Home page
CJASNHome page
J. A. Jaffe and P. L. Kimmel
Chronic Nephropathies of Cocaine and Heroin Abuse: A Critical Review
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 655 - 667.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. J. Schwartz, L. A. Szczech, M. J. Ross, M. E. Klotman, J. A. Winston, and P. E. Klotman
Highly Active Antiretroviral Therapy and the Epidemic of HIV+ End-Stage Renal Disease
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2412 - 2420.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP